Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110873 | 0.94 | HTR3A (0.44) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL5544343 | 0.92 | HTR3A (0.47) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL1366932 | 0.87 | HTR3A (0.46) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL315186 | 0.83 | HTR3A (0.58) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL435619 | 0.78 | HTR3A (0.59) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL218475 | 0.78 | HTR3A (0.59) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL5584293 | 0.77 | GRM2 (0.37) | TSHRSMN1; SMN2 | |
| SCHEMBL5584379 | 0.77 | KDM1A (0.40) | MEN1KMT2ASLC6A2SLC6A3CYP2C9 | |
| SCHEMBL8316351 | 0.77 | ESR2 (0.59) | CYP2C9 | |
| SCHEMBL241933 | 0.77 | KDM1A (0.40) | DRD2SLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-09-19 | — | — | US | claimed |
| EP-2635554-A2 | NOVEL NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | claimed |
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | claimed |
| WO-2012059443-A2 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | claimed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | claimed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | claimed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | claimed |
| WO-2001056974-A2 | INHA INHIBITORS AND THEIR USE AS ANTIBACTERIALS | GENZYME CORPORATION (US) | 2001-08-09 | — | — | WO | claimed |
| US-4179447-A | ANTIALLERGENS | WARNER-LAMBERT COMPANY (US) | 1979-12-18 | — | — | US | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-0574846-A2 | Imidazopyridines as angiotensin II antagonistes | MERCK PATENT GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
| US-4338453-A | Aminoalkyl-1,2,4-triazoles | THE UPJOHN COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4177290-A | CNS ACTIVITY | LABORATOIRE L. LAFON (FR) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | HTR3A 741/4885DRD2 211/4885SLC18A3 3852/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | HTR3A 4208/4885DRD2 4174/4885SLC18A3 3136/4885 |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | HTR3A 1617/4885DRD2 1957/4885SLC18A3 280/4885 |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | PRSS12, NLN, MTPN | HTR3A 1508/4885DRD2 696/4885SLC18A3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.